Search Results for “Pfizer” – Page 40 – media

ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults
- Source: Viivhealthcare
- 457
- March 28, 2018
HIV Juluca New Approvals
Novartis sells stake in joint venture to GSK for $13bn

Novartis has sold its stake in its consumer health joint venture with GlaxoSmithKline to its British rival for $13bn in an early move by Vas Narasimhan, the Swiss pharmaceuticals group's new boss, to focus on its core business.
- Source: Financial Times
- 516
- March 28, 2018
Company Insights healthcare pharmaceutical company
Improving health literacy is in pharma’s interests

Patients who understand the information provided about their health are more likely to adhere to a medicine regime and feel empowered to take steps towards healthier lifestyles. To what extent are pharma companies taking the initiative? Amanda Barrell reports.
- Source: PharmaPhorum
- 710
- March 28, 2018
Consumer Healthcare Market Views
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
- Source: tcr2
- 499
- March 23, 2018
blood cancer Market Views solid tumor TCR
EMA starts review of Xtandi in non-metastatic prostate cancer

The EU medicines regulator has started its review of Astellas and Pfizer’s prostate cancer drug Xtandi in what looks likely to become a hotly contested indication - non-metastatic castration-resistant prostate cancer (nmCRPC).
- Source: pmlive
- 813
- March 23, 2018
Astellas Company Insights nmCRPC Pfizer Xtandi
Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
- Source: Endpts
- 562
- January 23, 2018
Bavencio cancer inhibitor Market Views
Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, today announced the completion of a $58 million Series A financing. This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline. Polaris Partners, the founding investor that provided the initial seed funding, co-led the Series A financing along with Versant Ventures and Roche Venture Fund. SR One and BioInnovation Capital also participated in the round.
- Source: finance.yahoo
- 898
- January 22, 2018
antibody Company Insight immunomodulation
After disappointing 2016, new drug approvals roared back to life in 2017

New drug approvals all but screeched to a halt in 2016, with a measly 22 new OKs after a pair of bountiful years. But the FDA wasted no time in 2017, signing off on 12 drugs in the first quarter alone—besting its record for the same period of any year in recent history.
- Source: fiercebiotech
- 623
- January 4, 2018
CAR-T therapy FDA New Approvals new drug
Gene therapy shows promise against blood-clotting disease

Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.
- Source: Usnews
- 518
- December 12, 2017
blood disease gene hemophilia
First Video Game Therapy Heads to FDA As Akili Touts ADHD Study Win

For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
- Source: xconomy
- 490
- December 7, 2017
ADHD Attention Performance Index Company Insight video game

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.